Phase A — Understand the business
Lens 1 · Company Overview
Array makes the steel-and-software skeleton that points solar panels at the sun. Its core product is a single-axis tracker — motors, gearboxes, drivelines, torque tubes and controllers that rotate rows of PV modules east-to-west across the day, lifting energy yield and lowering the Levelized Cost of Energy (LCOE) versus a stationary "fixed-tilt" mount. The flagship is DuraTrack HZ v3 (launched 2015), whose patented design lets one motor drive multiple linked rows — the central structural claim of the moat (Lens 3). Around it sits a product family: OmniTrack (uneven terrain, less grading), SkyLink (grid-independent PV-powered controls, wireless, no trenching), the STI H250 dual-row tracker (from the 2022 Spanish STI acquisition), SmarTrack software (hail/snow/diffuse-weather stow algorithms), and — new in 2025 — APA foundation and racking systems (ground screws, helicals, c-piles, ballast).
Plain model: Array sells to solar developers, IPPs, utilities and EPCs under master supply agreements / multi-year procurement contracts, usually drop-shipped from outsourced suppliers straight to job sites. Revenue is recognized over time (cost-to-cost) on most projects — Q1-2026 was 77% over-time / 23% point-in-time. Since founding it has shipped >96 GW of trackers; FY2025 split 81% US / 19% rest-of-world. HQ: Albuquerque, New Mexico; ~283,000 sq ft domestic plant plus a new ~176,000 sq ft Bernalillo County facility coming online H1-2026, plus STI manufacturing in Spain (~67k sq ft) and Brazil (~610k sq ft).
Contract structure / payment terms. Contracts run "hundreds of thousands to tens of millions of dollars," with delivery from days to several months — i.e. short-cycle, not take-or-pay. Array can decline fixed-price or commodity-indexed multi-year contracts it deems too risky ("Structured Cost Management"), accepting that this pushes some volume to competitors. Customer concentration is real but moderate: in FY2025 the two largest customers were ~13.7% and ~12.2% of revenue; top-5 = ~29.8% of receivables.
Lens 2 · Supply Chain
Upstream inputs → Array → end customer, named where the filings name them:
- Raw materials: steel tubing, steel supports, aluminum extrusions (clamps, U-joints, bearing housings), electric motors, gearboxes, bearing assemblies, drivelines, electronic controllers. Steel and aluminum are the dominant cost drivers; Array does not hedge raw-material prices. This is the single most important supply-chain fact: margins ride bare on steel/aluminum and tariffs.
- Suppliers/manufacturing model: Array deliberately outsources capital-intensive, low-value-add fabrication (steel tubing, supports, drivelines, bearings, gearboxes, motors, controllers ship direct from suppliers to job sites). It assembles module clamps, center structures and motor-controller assemblies in-house at Albuquerque. Named related-party leases (Ohio/Connecticut) came with APA — five leases are with related parties owned by APA management (flagged again in Lens 9/10).
- 45X benefit-sharing: Array negotiates with suppliers of torque tubes and structural fasteners to split the Section 45X advanced-manufacturing PTC; it also self-manufactures certain 45X-eligible parts. The 45X economics are a live margin lever and a live risk (OBBB FEOC limits).
- Logistics chokepoints (named): Red Sea / Suez shipping disruption (Asia routes), Strait of Hormuz risk from the March-2026 US/Israel–Iran conflict driving commodity/freight costs, and Brazilian Real depreciation hammering the STI segment.
- Downstream chokepoint NOT in Array's control: high-voltage breakers, switches and transformers for grid interconnection are in shortage and gate when projects actually get built. Array can ship a tracker; if the developer can't get a transformer, revenue slips a quarter.
Single-source / concentration risk: Array claims redundancy ("identified certain alternative vendors") and the ability to in-source, but the outsourced steel/aluminum chain means AD/CVD and Section 232 metal tariffs flow almost directly into cost per watt (CPW). The chain is US-centric for the Legacy segment (a deliberate tariff hedge) and Spain/Brazil-centric for STI.
Lens 3 · Competitive Advantages (moats)
The moat is real but narrow, and it has a clock on it.
- The linked-row patent. Array's core US patent on a single-motor, linked-row rotating-gear-drive system "does not expire until February 5, 2030." Competitors must use designs Array argues are inherently less efficient (e.g. one motor per row). IP estate: 74 issued US patents, 174 non-US, 216 pending; US patents expire 2030–2045. This is a genuine, datable switching/design-around advantage — but the flagship's foundational claim lapses in 2030, ~4 years out.
- 100% domestic-content capability — the 2026 moat that matters most. Array (and Nextracker) can deliver 100% US-content trackers, letting customers claim the IRA/OBBB domestic-content bonus credit and dodge the FEOC "prohibited foreign entity" trap. Sell-side notes Array has booked 100%-domestic-content orders and is cutting tariff-exposed BOM to <14%. In a post-OBBB world where Chinese supply is being cut off, this is a structural tailwind to relative share even as the absolute US market faces a credit cliff.
- 45X benefit capture — Array converts torque-tube/fastener 45X credits into margin via supplier-sharing deals (Lens 2). Durable only as long as 45X survives and FEOC rules don't disqualify the parts.
- Bargaining power: weak-to-balanced. Array sells to large, sophisticated buyers (Tier-1 utilities, IPPs) who often dictate the tracker spec; it buys commodity steel/aluminum it can't hedge. It is a price-taker on inputs and a spec-taker on the demand side — the moat is product design + domestic footprint, not pricing power. Its willingness to walk from bad fixed-price contracts is a discipline signal, not a moat.
Versus rivals on perceived value: Array competes on LCOE, reliability, warranty duration and US-content. It is not the share leader (Lens 7) — Nextracker out-innovates (robotics/AI division via OnSight) and out-scales it ~3:1. Array's edge is the patent + a credible domestic-manufacturing story, not brand dominance.
Lens 4 · Segments
Two reportable segments. segments.csv is empty, so all figures are from the filings' segment tables.
By segment — FY2025 vs FY2024:
| Segment | FY2025 rev | FY2024 rev | YoY | FY2025 gross profit | FY2025 GM |
|---|
| Array Legacy Operations (US + APA) | $1,070.5M | $661.6M | +62% | $300.0M | 28% (was 41%) |
| STI Operations (Spain/Brazil) | $213.7M | $254.2M | −16% | $(1.4)M | (1)% (was 11%) |
| Total | $1,284.1M | $915.8M | +40% | $298.6M | 23% (was 33%) |
By segment — Q1-2026 vs Q1-2025:
| Segment | Q1-26 rev | Q1-25 rev | YoY | Q1-26 GM |
|---|
| Array Legacy (US + APA) | $217.4M | $213.2M | +2% | 30.0% |
| STI Operations | $6.0M | $89.1M | −93% | (37.4)% |
| Total | $223.4M | $302.4M | −26% | 28.2% |
The story the segments tell: Array is now a US business with a smoldering crater where Brazil used to be. The Legacy segment (with APA bolted on Aug-2025) is growing volume and holding ~28–30% gross margin. STI — the Spanish/Brazilian operation — has imploded: −93% revenue and a negative 37% gross margin in Q1-2026, driven by Brazilian PPA economics collapsing under a weak Real and pricing pressure. Array has already (a) taken a $29.5M one-time inventory valuation charge on STI in 2025, (b) recorded $102.6M of STI goodwill impairment in 2025 (on top of $236.0M in 2024 — see Lens 10), (c) approved a plan to phase out the non-SmarTrack H250 and resize international operations, and (d) signaled intent to push the flagship DuraTrack through STI's channel. Translation: the entire STI thesis is being rebuilt mid-air, and until it is, it is a margin drag, not a contributor.
By geography: FY2025 = 81% US / 19% RoW. The mix is becoming more US-weighted as STI shrinks and APA (US) grows — which is strategically defensible given OBBB/FEOC but concentrates Array into a single policy regime.
Phase B — Measure performance
Lens 5 · Earnings Result (latest print = Q1-2026, period ended 2026-03-31)
[All figures research-layer: filings/10-q-2026-q1.md unless labeled.]
- Revenue $223.4M, −26% YoY (vs $302.4M) — but this is seasonal + STI collapse, not core US weakness (Legacy +2%). Q1/Q4 are structurally Array's weak quarters (Lens 8 seasonality).
- Beat vs consensus: revenue $223.4M beat the ~$205.9M Street estimate; adjusted net income/diluted share $0.06 beat the −$0.05 consensus loss.
- Gross profit $63.0M; GAAP gross margin 28.2%, UP from 25.3% YoY — the headline positive. Adjusted gross margin 30.7%. Margin is expanding even as revenue shrinks, because the mix shifted to higher-margin US Legacy and 45X benefits landed.
- Income from operations $7.1M (down from $27.3M — flattered last year by no impairment this quarter; the YoY op-income drop is the revenue decline, not a cost blowout).
- GAAP net income $2.0M. BUT — the punchline — after $15.5M of preferred dividends & accretion, net loss to common = $(13.5)M, EPS $(0.09) (vs +$0.02 PY). Adjusted EPS was +$0.06. The gap between $2.0M net income and a $(13.5)M loss to common is the Series A preferred (Lens 10 / Devil's Advocate).
- Adjusted EBITDA $28.8M.
- Order book / backlog — TWO numbers, both true, do not conflate:
- GAAP Remaining Performance Obligations = $544.0M as of 2026-03-31, 94% recognizable within 12 months. This is the binding, revenue-recognizable backlog. (Was $400.6M at Q3-2025 — a healthy sequential build.)
- "Total executed contracts and awarded orders" = record $2.4B. This is the IR non-GAAP "order book," includes awarded-but-not-yet-binding orders, and is the figure the press repeats. 2x quarterly book-to-bill, 1.3x TTM book-to-bill.
- Balance-sheet flags: operating cash flow NEGATIVE $(29.4)M (vs −$13.1M PY) — Q1 is a working-capital drain quarter; cash fell to $200.7M (from $244.4M at YE2025). Inventory rose to $168.0M (from $150.4M) and unbilled receivables to $110.5M — receivables/inventory building ahead of the Q2/Q3 seasonal ramp (consistent with guidance) but worth watching. IRA vendor-rebate receivable $164.7M (45X economics owed by suppliers) is a large, policy-dependent asset.
- Guidance / tone (reaffirmed at Q1): FY2026 revenue $1.4–1.5B, adjusted EBITDA $200–230M, adjusted net income/share $0.65–0.75. Q2-2026 guided to $300–320M revenue — i.e. management is telling you the seasonal ramp is intact and H2-weighted.
- Market reaction: modestly positive (up ~1.7–4% after the print; one source cited +10.6% after-hours). The stock had risen ~57% over the prior year off the 2025 trough.
Unusual vs its own history: margin expanding while revenue contracts (good), but a GAAP net-loss-to-common despite GAAP net income (structural preferred drag) and negative operating cash flow (seasonal). The single most "unusual" item is the STI segment at −37% gross margin — that is not normal and is the active wound.
Lens 6 · Earnings Calls (sentiment trend)
transcripts/ is empty on the shelf; this lens is `` + filing-derived MD&A tone.
- Tone arc, FY2024 → Q1-2026: From defensive (2024 was dominated by two consecutive STI goodwill impairments, a sliding stock hitting 52-week lows, and IRA-guidance uncertainty) → to cautiously confident in 2025–2026. The recurring phrases now: "record order book," "100% domestic content," "margin expansion," "disciplined international expansion," "APA integration progressing well".
- What management started saying: domestic-content as a competitive weapon; APA synergies; book-to-bill > 1.
- What they stopped saying: the aggressive Brazil/international growth story — replaced by "resize," "realign cost structure," "phase out" the non-SmarTrack H250. The pivot from "grow STI" to "shrink and fix STI" is the clearest sentiment shift.
- Management focus (stated): "high-quality domestic opportunities while pursuing disciplined international expansion" — CEO Hostetler. Read: defend the US franchise, stop bleeding overseas.
Lens 7 · Comps
Peers from the 10-K's own stock-performance peer group (Enphase, SolarEdge, Shoals, FTC Solar) plus the only true direct tracker peer, Nextracker (now "Nextpower," NXT). Multiples are ``; where not sourced, marked n/a.
| Company | Ticker | Mkt cap | EV/Sales | EV/EBITDA | P/E | Div yield | 5-yr avg ROE | Note |
|---|
| Array Technologies | ARRY | ~$1.40B | ~1.29x | ~9.3x | n/a (GAAP loss to common) | 0% | negative (impairment-driven losses) | #2 tracker |
| Nextracker / Nextpower | NXT | n/a | ~3.84x | ~17.6x | n/a | n/a | n/a | #1 tracker, ~26–35% global share |
| FTC Solar | FTCI | n/a | ~0.14x | n/a | n/a | 0% | negative | sub-scale, survival mode |
| Shoals Technologies | SHLS | n/a | n/a | n/a | n/a | n/a | n/a | eBOS, not trackers |
| Enphase | ENPH | n/a | n/a | n/a | n/a | n/a | n/a | microinverters (residential) |
| SolarEdge | SEDG | n/a | n/a | n/a | n/a | n/a | n/a | inverters |
Read: Array trades at roughly half Nextracker's multiple on both EV/Sales (1.29x vs 3.84x) and EV/EBITDA (9.3x vs 17.6x). That discount is partly earned — Nextracker is ~2.8x the revenue ($3.56B vs $1.28B), has a >$5.25B backlog vs Array's $2.4B order book / $544M GAAP RPO, FY2026 adj EBITDA $810–830M vs Array's $200–230M, adj EPS $4.26–4.36, GAAP-profitable, and out-innovating (AI/robotics division). The bull's argument is the gap is too wide given Array's comparable domestic-content position and expanding margins. The bear's argument is that the discount reflects real inferiority: smaller, slower, no GAAP common earnings, a crater segment, and a preferred overhang Nextracker doesn't carry. The comp is not "cheap Nextracker" — it is "the clear #2 priced as the clear #2." Enphase/SolarEdge/Shoals are different sub-sectors (inverters/eBOS) and only loosely comparable; FTC Solar (EV/Sales ~0.14x) is the sub-scale failure case and a reminder that scale is destiny in this industry.
Lens 8 · Stock-Price Catalysts (what moves ARRY >5%)
Mostly ``, cross-checked to filing events.
- 52-week range ~$4.52 – $12.23; currently ~$7.93–$9.08. A stock that has nearly 3x'd off its trough and round-tripped inside a year — extreme policy-beta.
- Pattern of >5% moves:
- Policy/legislative headlines dominate. The mid-2025 OBBB signing (Jul-4-2025: ITC termination for projects placed in service after 12/31/2027 unless construction begins before 7/4/2026) and the cascade of Treasury notices, FEOC rules, and AD/CVD determinations drove sector-wide double-digit swings. Array is a policy-beta name first, a fundamentals name second.
- Earnings prints — Q1-2026 beat (revenue + adj EPS + record order book) → modest pop; 2024's STI impairments + lowered outlook → 52-week lows.
- Tariff/trade rulings — the Feb-2026 SCOTUS ruling that IEEPA does not authorize tariffs (struck the reciprocal/fentanyl tariffs; collection ceased 2/24/2026), the temporary Section-122 10% surcharge (expires 7/24/2026), and the new Section-232 full-customs-value metal-tariff scheme (Apr-2026) all move solar-supply-chain sentiment.
- Macro rates — developer financing economics swing with the Fed; "customers delay installations awaiting rate cuts."
- What the market actually reacts to for ARRY: US solar policy and tariffs, then book-to-bill, then margin. It is not an idiosyncratic-execution name — it trades with the policy tape. That is the single most important fact for sizing a position: your timing risk is a Treasury notice or a court ruling, not a product cycle.
Phase C — Judge people & books
Lens 9 · Management
- CEO: Kevin Hostetler (since April 2022). Career industrials operator, 25+ years; previously CEO of Rotork plc (UK flow-control), where he ran a "Growth Acceleration Program" lifting margins and capital efficiency. Archetype: professional turnaround/operations manager, not founder. That fits Array's stage — this is a margin-and-execution story, and Hostetler's resume is margin-and-execution. The 2025–2026 playbook (resize STI, integrate APA, push domestic content, expand gross margin) is textbook industrial-operator behavior.
- Track record at Array (quantified): Took gross margin from a 2024 trough through two brutal impairment years and delivered FY2025 +40% revenue and Q1-2026 margin expansion to 28.2% GAAP / 30.7% adj — credible. But also oversaw the STI value destruction (two goodwill impairments totaling $338.6M across 2024–2025, a $29.5M inventory charge) — though much of STI's deterioration is Brazilian macro, the original STI thesis (bought Jan-2022) has been a value-destroyer on his watch.
- Skin in the game / ownership: Insiders hold only ~0.41% of the company; institutions ~83%. This is a PE-incubated public company: Oaktree Capital was the IPO parent and remains a ~10% owner; Chairman Brad Forth is ex-Oaktree MD / Neos Partners. Low direct insider ownership = limited founder-style alignment; the alignment that exists is institutional/PE.
- Capital-allocation history: Mixed-to-deteriorating on ROIC. (a) STI acquisition (2022) → $338.6M of impairments — a capital-allocation black mark. (b) APA acquisition (Aug-2025, $185.4M) — too early to judge; contributed $14.9M revenue but a $10.2M operating loss in Q1-2026 (loaded with deferred comp + amortization); thesis is foundation/racking cross-sell + synergies. (c) Debt management is the genuine bright spot: in 2025 they refinanced out of the Term Loan via the 2031 convertible notes (2.875%), repurchased $100M of 2028 notes at a gain, and in Feb-2026 expanded the revolver from $166M to $370M and pushed maturity to 2031 (Fifth Amendment, Goldman as agent) — de-risking the near-term balance sheet materially. (d) Capped calls raise the 2031 conversion price to $12.74 and the 2028 to $36.02, limiting dilution.
- Red flags (governance): Five APA leases are with related parties owned by APA management, and the principal APA seller still runs APA; the APA earnout/deferred consideration is tied to continued employment (compensatory) — related-party complexity to monitor, not yet a scandal. No dividend ever paid on common. Heavy reliance on a TRA (tax receivable agreement) owed to a former indirect stockholder.
- Net: competent industrial operator with a real margin story and excellent recent balance-sheet stewardship, carrying the scar tissue of a value-destroying international acquisition and the structural awkwardness of a PE-legacy cap table with thin insider ownership.
Lens 10 · Forensic Red Flags
Forensic-analyst lens. All figures research-layer: filings/ unless noted.
- The headline GAAP-vs-common gap (most important). Net income of $2.0M (Q1-26) becomes a $(13.5)M loss to common because of $15.5M/quarter of preferred dividends + accretion on the Series A Redeemable Perpetual Preferred (400,000 shares, $1,000 liq pref = $400M face, issued 2021 for ~$395.4M). It accrues at 6.25% PIK until the 5th anniversary — Aug 11, 2026 — then must be paid in CASH at 5.75%+ (stepping up 50bps on the 5th/6th/7th anniversaries, 100bps on the 8th–10th). Accrued unpaid dividends already total $98.5M. This is the dominant forensic feature: a large, compounding, soon-to-be-cash claim that sits senior to common and converts operating profit into common-shareholder losses. It is classified as temporary (mezzanine) equity, not debt — so leverage screens understate the true senior claim on the business.
- Earnings vs cash flow divergence. Q1-2026 GAAP net income +$2.0M but operating cash flow −$29.4M — explained by a $50.6M working-capital outflow (seasonal inventory + unbilled-receivable build ahead of the Q2/Q3 ramp). FY2025 OCF was +$101.8M on a GAAP net loss of $52.2M — the loss being non-cash impairment. So the divergences are explainable (impairment one way, seasonal WC the other), not obviously manipulative — but the rising inventory ($168M) and unbilled receivables ($110.5M) deserve monitoring; if the H2 ramp disappoints, that working capital becomes trapped.
- Goodwill / impairment history (a genuine flag). $338.6M of STI goodwill+asset impairment across 2024–2025 ($236M + $102.6M goodwill, plus $91.9M long-lived in 2024, plus the $29.5M inventory charge). Goodwill still carried at $135.2M (all Array Legacy) post-impairment; intangibles net $224.9M. The repeated impairments show the STI purchase price was badly wrong; the remaining Legacy goodwill looks defensible (no 2025 Legacy impairment indicators) but is not immune if US demand cracks.
- Non-GAAP flattery. The spread between adjusted EPS +$0.06 and GAAP EPS −$0.09 (Q1-26) is driven by add-backs for amortization of acquired intangibles, acquisition/deferred-comp expense, and — critically — adjusted metrics that sit above the preferred dividend line. "Adjusted net income per common share $0.65–0.75" guidance is before the full weight of the soon-to-be-cash preferred. SBC and acquisition deferred-comp ($5.0M in Q1) are real costs being normalized away.
- Tax volatility. Effective tax rate 51.6% in Q1-26 (vs 28.1% PY) and a swing to $23.0M tax expense in FY2025 despite a pre-tax loss — driven by a goodwill-impairment reversal for tax purposes (+$22.3M) and a Brazil valuation allowance. Tax is noisy and jurisdiction-mix-driven; not a red flag per se but reduces earnings-quality predictability.
- Related-party leases / TRA — see Lens 9. Monitor.
Regulatory findings (required sub-section).
- SEC Litigation Releases / AAERs: None. Per
regulatory/regulatory-findings.md (fetched 2026-06-18, EDGAR EFTS LR+AAER, 2021–2026): 0 SEC LR, 0 AAER naming Array Technologies.
- Item 3 Legal Proceedings (10-K, quoted/labeled and updated ):
- Plymouth securities class action (filed May-2021, SDNY): alleged §10(b)/§11 misstatements/omissions tied to the Oct-2020 IPO and 2020–2021 secondary offerings. Dismissed with prejudice May-2023; the Second Circuit AFFIRMED the dismissal with prejudice on March 24, 2026 — i.e. this multi-year securities overhang is now resolved in Array's favor. A material removal of risk in the latest quarter.
- Derivative suits: the SDNY derivative action was voluntarily dismissed April 28, 2026 following the Plymouth affirmance; the Delaware Court of Chancery derivative cases remain stayed.
- SWSS arbitration (served Sep-2025): contractual/negligence claim by Sterling & Wilson Solar Solutions over a Bickleton, WA project; Array is vigorously defending, stay requested Apr-2026, no material loss contingency accrued, damages unknown but characterized as early-stage. Not material on current facts.
- Non-SEC enforcement (web search): No material FTC/DOJ/FDA/CFPB enforcement, consent decree, fine, or penalty against Array Technologies surfaced. The relevant "regulatory" exposure is trade/tariff (AD/CVD on imported cells/modules from SE Asia + India/Indonesia/Laos; the First Solar Section-337 TOPCon exclusion-order case that could constrain module supply to Array's customers) — these are industry trade actions, not enforcement against Array.
- Conclusion: No material regulatory or enforcement findings against the company — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-18. The historic IPO securities litigation is now resolved (dismissed with prejudice, affirmed Mar-2026).
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028 EPS)
Bottom-up from FY2025 actuals + management's reaffirmed FY2026 guidance. All outputs ``; the preferred drag is the swing factor — I project both adjusted (pre-full-preferred) and a common-shareholder GAAP-style view.
Anchors:
- FY2025 actual: revenue $1,284M, GAAP net loss $(52.2)M, GAAP loss to common ~$(118)M-equiv after ~$59M preferred (4 quarters × ~$14.5–15.5M), adj EBITDA ~$155M-range [implied; web Q-by-Q].
- FY2026 guidance: revenue $1.4–1.5B, adj EBITDA $200–230M, adjusted net income/share $0.65–0.75.
- Share count ~153M; preferred dividends rising (turns cash Aug-2026), ~$62–66M/yr and climbing.
FY2026 (base): Take guidance midpoint — revenue ~$1.45B, adj EBITDA ~$215M, adjusted EPS ~$0.70. On a common-shareholder GAAP basis, after $64M preferred, real D&A ($110M/yr intangibles + PP&E) and interest, GAAP EPS to common is likely roughly breakeven-to-slightly-negative (~$(0.05)–$0.10). The honest read: adjusted ~$0.70; GAAP-to-common ~flat.
- Bull FY2026: revenue $1.5B, adj EBITDA $230M, adj EPS $0.75; safe-harbor pull-forward + 100%-content share gains + STI stops bleeding.
- Bear FY2026: revenue $1.35B (safe-harbor demand pulls into early-2026 then air-pocket; project delays from transformer/interconnection + AD/CVD module shortages), adj EBITDA ~$180M, adj EPS ~$0.55, GAAP-to-common clearly negative.
FY2027 (base): This is the OBBB air-pocket year. Projects must begin construction before Jul-4-2026 to keep the ITC; demand likely pulls forward into 2026 and decelerates in 2027 unless technology-neutral credits + data-center load offset. Base: revenue ~$1.35–1.45B (flat-to-slightly-down), adj EBITDA ~$200–215M, adj EPS ~$0.65–0.70. The preferred turning cash-pay in Aug-2026 is a real FCF hit from FY2027 on.
- Bull FY2027: AI/data-center power demand + 100%-content moat sustain US volume; STI recovers to breakeven; adj EPS ~$0.85.
- Bear FY2027: post-safe-harbor demand cliff is severe; revenue −15–20%; adj EPS ~$0.40, GAAP-to-common deeply negative, FCF pinched by cash preferred.
FY2028 (base): Two-sided. The core linked-row patent expires Feb-5-2030 (still ahead), but the ITC fully terminates for projects placed in service after 12/31/2027 — FY2028 is when post-cliff demand reality bites and when "solar is cost-competitive without subsidy" gets tested. Base: revenue ~$1.4–1.55B (recovery if data-center/merchant solar fills the policy gap), adj EBITDA ~$210–235M, adj EPS ~$0.70–0.80.
- Bull: unsubsidized US utility-solar + AI load = secular growth resumes, adj EPS ~$1.00+.
- Bear: subsidy-cliff demand destruction + patent-cliff approaching = adj EPS ~$0.45, structural de-rating.
Forecast NOT logged — per --watchlist unattended rules, forecast.ts create is skipped (only log a Brier forecast on genuine committed conviction in a /thesis pass). The base call for tracking would be: "ARRY FY2026 adjusted net income/share ≥ $0.65" (p≈0.60, resolves 2027-02) — recorded here for the analyst, not written to the tracker.
Lens 12 · Bull vs Bear
Bull case. Array is the #2 in a structurally growing, oligopolistic industry (top-3 US suppliers = >90% share) trading at half the #1's multiple. It owns a datable patent moat to 2030 and — more importantly for this policy cycle — a 100%-domestic-content capability that makes its trackers the FEOC-safe, bonus-credit-eligible choice exactly as OBBB cuts off Chinese supply. Margins are expanding (28.2% GAAP / 30.7% adj, up YoY) even as revenue dips on seasonality + STI. The balance sheet was just de-risked (Term Loan repaid, revolver expanded to $370M / 2031, converts pushed to 2028/2031 with capped calls). The order book is at a record $2.4B with 2x book-to-bill, and the IPO securities litigation just got dismissed with prejudice (affirmed Mar-2026), removing a multi-year overhang. AI/data-center power demand is a fresh secular tailwind to US utility-scale solar. If STI merely stops bleeding and APA synergies land, the EBITDA base ($200–230M) supports meaningful equity value at 9x EBITDA. Earnings surprise vector: safe-harbor-driven 2026 demand pull-forward + margin beats.
Bear case (2–3 permanent-impairment risks).
- The preferred is a permanent tax on common. $400M face compounding at 6.25%→cash from Aug-2026, $98.5M already accrued, $15.5M+/quarter — it converts operating profit into common-shareholder losses and will drain FCF in cash from FY2027. Unless redeemed/refinanced (expensive at this stock price), common holders sit behind a perpetual senior claim. This is not cyclical; it is structural.
- The OBBB safe-harbor cliff is a demand time-bomb. Projects must begin construction before Jul-4-2026 to keep the ITC; the credit terminates for placements after 12/31/2027. The most likely shape is 2026 pull-forward → 2027 air-pocket. A tracker vendor with a $544M GAAP RPO that's 94% recognizable within 12 months has almost no multi-year visibility through the cliff — the $2.4B "order book" includes non-binding awarded orders that can evaporate if developer economics break.
- Permanent #2 status + a fixable-but-unfixed crater. Nextracker out-scales (~2.8x revenue, >$5.25B backlog), out-earns (GAAP-profitable, $810M+ EBITDA), and out-innovates (AI/robotics). STI is at −37% gross margin and being rebuilt mid-air. Array is a price-taker on un-hedged steel/aluminum with no pricing power.
Pre-mortem (it's Dec-2027, the thesis broke — what happened?): The 2026 safe-harbor rush pulled demand forward; 2027 US utility-solar bookings fell off a cliff as the ITC expired and merchant/data-center demand didn't fill the hole fast enough. STI never recovered. Array's $2.4B "order book" shrank as awarded-but-non-binding orders were cancelled when developer IRRs collapsed. The preferred went cash-pay, FCF turned negative, and the stock de-rated to ~5x trough EBITDA. The 9x multiple was not "cheap" — it was the right multiple for a sub-scale #2 facing a policy cliff with a senior-claim overhang.
Are multiples too high? No — at ~9x EBITDA / 1.29x sales, Array is not expensively priced; the risk is earnings, not multiple. A multiple this low can still fall if EBITDA falls.
Contrarian view (what the market is refusing to see): The bears are over-anchored on the OBBB cliff and under-weighting that OBBB simultaneously hands Array a relative-share gift — by enforcing FEOC and domestic content, it kneecaps the Chinese-supplied competition and makes 100%-content trackers the only credit-safe option. The contrarian bet is that Array's share of a shrinking-then-stabilizing US market rises faster than the market shrinks, and AI-data-center load arrives sooner than the consensus 2027-air-pocket model assumes. The non-contrarian risk that everyone should see but the price doesn't fully reflect: the preferred turning cash in Aug-2026 is a near-certain, datable FCF event, not a tail risk.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case.
- What structurally breaks the money machine? Demand is 100% policy- and rate-dependent, recognized over-time on short-cycle contracts with no multi-year backlog visibility ($544M GAAP RPO, 94% within 12 months). A single Treasury notice, court ruling, or rate surprise re-rates the whole sector — and Array trades as pure policy-beta (52-week range $4.52–$12.23 = a ~2.7x peak-to-trough). The short thesis doesn't even need Array to do anything wrong; it needs the 2027 ITC air-pocket to be as bad as the mechanism implies.
- Where is revenue concentrated, and what if it shifts? Now ~81% US and rising — a single regulatory regime. Top-2 customers ~26% of revenue. If two large IPP customers push projects right (transformer shortages, financing), a quarter craters (see Q1-26 STI −93%).
- Why is the moat weaker than bulls think? The flagship's core patent expires Feb-2030; design-arounds are already in market (Nextracker, GameChange). "100% domestic content" is matched by Nextracker — it is table stakes among the US top-3, not a unique edge. There is no pricing power (un-hedged commodity inputs, spec-taking customers).
- Most dangerous competitor bulls underestimate: Nextracker. It is not just bigger — it is GAAP-profitable, has a >$5.25B backlog (10x Array's GAAP RPO), and just launched an AI/robotics division. In an oligopoly, the scale leader compounds its lead (procurement, R&D, balance sheet). Array risks being permanently out-invested.
- Worst capital-allocation moves: the STI acquisition → $338.6M impaired. That is the tell on management's M&A judgment — and they just did another $185M deal (APA) that's currently running an operating loss with related-party leases and an employment-tied earnout. Pattern risk.
- What must hold for today's ~$9 price? FY2026 adj EBITDA $200–230M and a market willing to look through the 2027 cliff and the preferred not forcing a dilutive/expensive refinancing and STI stabilizing. That's a lot of "ands."
- If growth disappoints 20–30%: FY2027 revenue ~$1.0–1.15B, adj EBITDA ~$120–150M, GAAP-to-common deeply negative, FCF pinched by the now-cash preferred. At a de-rated 6x trough EBITDA → EV ~$720M–900M, less ~$680M net debt and the $400M+ preferred claim → equity value compresses violently. This is a high-operating-and-capital-structure-leverage name.
- Single scenario that permanently impairs: The 2027 ITC air-pocket + a stalled merchant/data-center bridge + the preferred going cash. Plausibility: moderate-to-high on the demand cliff (it's legislated), lower on it being permanent (solar economics + AI load argue for eventual recovery). The permanent impairment is to the common stake specifically, via the preferred — not necessarily to the enterprise.
Lens 14 · Management Questions (ordered by information value)
- The Series A preferred turns cash-pay in August 2026 at 5.75%+, with $98.5M already accrued. What is the explicit plan — redeem, refinance, let it accrue at the default rate, or convert — and at what cost to common, given the current share price? (This single answer most changes the view — it's the structural overhang.)
- Your GAAP RPO is $544M (94% within 12 months) but you report a $2.4B "order book." Walk me through the bridge: how much of the $2.4B is binding vs awarded-but-cancellable, and what cancellation rate have you actually seen when developer IRRs compress?
- Model the 2026 safe-harbor pull-forward vs the 2027 ITC air-pocket. How much of FY2026's $1.4–1.5B guide is demand borrowed from 2027, and what is your internal FY2027 US-volume assumption?
- STI ran a −37% gross margin in Q1-2026. What is the concrete path and timeline to breakeven — and at what point do you exit Brazil/Spain entirely rather than fund another impairment?
- After $338.6M of STI impairment, why was APA the right $185M use of capital — and what specific, quantified synergies justify it by when? Why is it running an operating loss two quarters in?
- Nextracker is ~2.8x your revenue, GAAP-profitable, with a >$5.25B backlog and a new AI/robotics division. Where do you structurally out-compete them in the next 3 years rather than just hold #2?
- The core linked-row patent expires February 2030. What protects the franchise post-2030 — what's in the 216 pending applications that extends the moat, and how do you quantify the design-around threat today?
- You don't hedge steel or aluminum and have no pricing power on inputs. With Section-232 metal tariffs now on full customs value, what's the realistic 2026–2027 CPW trajectory, and how much can 45X + domestic-content actually offset?
- If 45X eligibility or the domestic-content bonus is altered by future Treasury rulemaking or FEOC reinterpretation, what's the dollar impact to gross margin? How much of your $164.7M IRA vendor-rebate receivable is at risk?
- Operating cash flow was −$29.4M in Q1 with inventory and unbilled receivables building. What's the full-year FCF bridge, especially once the preferred is cash-pay, and do you stay FCF-positive in a 2027 demand-down scenario?
- Insider ownership is ~0.41% and Oaktree remains a ~10% holder from the IPO. How is management's compensation tied to per-common-share value creation rather than adjusted metrics that sit above the preferred line?
- Five APA leases are with related parties owned by APA's management, and the earnout/deferred consideration is employment-tied. What governance guardrails prevent related-party leakage as you integrate?
- The First Solar Section-337 TOPCon case could trigger a general exclusion order constraining US module supply. How does a module-supply shock to your customers flow through to tracker demand — is it a net headwind or, via domestic-content, a relative tailwind?
- AI/data-center load is the new secular bull narrative for US solar. How much of your current order book is explicitly tied to data-center-adjacent projects, and how durable is that demand if the AI capex cycle cools?
- What single development over the next 18 months would most change your view of this business — and what's the leading indicator we should watch for it?